Is Replimune Group Inc (REPL) overvalued? · $825.7M cap
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
This page asks whether Replimune Group Inc (REPL) looks expensive on cached numbers — not a short thesis.
No cached income statement for REPL, so there is no earnings base to call rich or cheap.
REPL currently screens at market cap $825.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next REPL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the REPL stock page for the full model, not this heading.
Not investment advice.